Le Lézard
Classified in: Health, Science and technology
Subject: MISCELLANEOUS

Junshi Biosciences Announces Approval of "B" Marker Removal from Company's Stock Name by HKEX


SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that following its application to The Stock Exchange of Hong Kong Limited (HKEX) pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on HKEX (Listing Rules), HKEX has granted approval for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules. Junshi Biosciences originally listed on the HKEX on December 24, 2018 under Chapter 18 A (the biotech chapter) of the Listing Rules. It now satisfies and even well surpasses the revenue and market capitalization requirements for the dis-application.

As a result of the approval by the HKEX, the "B" marker will no longer be affixed to the Company's stock name in the HKEX.

About Junshi Biosciences

Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with effective and affordable treatment options. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK. The Company has established a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic diseases, autoimmune diseases, and neurologic diseases. Product types include monoclonal antibodies, fusion proteins, antibody drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP facilities at Shanghai and Wujiang, Junshi has established the manufacturing infrastructure to support commercialization and provide our partners and patients with high-quality products through a global supply chain network. For more information, please visit: http://junshipharma.com/en/Index.html

Contact Information

IR Team:
info@junshipharma.com  
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+1 646-389-6658


These press releases may also interest you

at 16:20
Aspen Technology, Inc. , the asset optimization software company, today announced a new AIoT Hub, a result of the integration of its recent investments in Industry 4.0 capabilities. The new AIoT Hub enables seamless and flexible data mobility and...

at 16:20
CACI International Inc , a leading provider of expertise and technology to government enterprise and mission customers, announced results today for its fiscal fourth quarter and full year ended June 30, 2020. CEO Commentary and Outlook John...

at 16:20
ADC Therapeutics SA , a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid...

at 16:20
CACI International Inc announced today it has acquired Ascent Vision Technologies, LLC (AVT), a leading provider of technology and solutions that support multi-domain intelligence, surveillance, and reconnaissance (ISR), unmanned aircraft system...

at 16:20
BioUtah President and CEO, Kelvyn Cullimore, issued the following statement following the announcement of the opening of Altitude Lab. "This is truly a life sciences milestone in Utah. We applaud Recursion and the University of Utah for their...

at 16:16
Today, Inc. magazine revealed that Brillient Corporation has appeared for the fifth time on its annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing private companies. Brillient was recognized for its 66.86% growth over...



News published on 12 july 2020 at 08:25 and distributed by: